{
  "resourceType" : "PlanDefinition",
  "id" : "RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients",
  "meta" : {
    "profile" : ["https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/recommendation"]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: PlanDefinition RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients</b></p><a name=\"RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients\"> </a><a name=\"hcRecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients\"> </a><a name=\"RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients-en-US\"> </a><p><b>url</b>: <a href=\"PlanDefinition-RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients.html\">PlanDefinition Therapeutic anticoagulation in non-intensive care, high-risk COVID-19 patients</a></p><p><b>version</b>: 1.0</p><p><b>name</b>: 17 - Therapeutic Anticoagulation</p><p><b>title</b>: Therapeutic anticoagulation in non-intensive care, high-risk COVID-19 patients</p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/plan-definition-type workflow-definition}\">Workflow Definition</span></p><p><b>status</b>: Active</p><p><b>experimental</b>: true</p><p><b>date</b>: 2022-02-14</p><p><b>publisher</b>: Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin e.V. (DGIIN)</p><p><b>description</b>: </p><div><p>Bei hospitalisierten, nichtintensivpflichtigen Patienten mit COVID-19 und erhöhtem Risiko (z.B. D-Dimere ≥ 2 mg/l) kann bei niedrigem Blutungsrisiko eine therapeutische Antikoagulation, präferenziell mit NMH oder UFH, erwogen werden.</p>\n</div><h3>Actions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Title</b></td><td><b>Description</b></td><td><b>Code</b></td><td><b>Definition[x]</b></td></tr><tr><td style=\"display: none\">*</td><td>Therapeutic_Anticoagulation_No_Renal_Function_Impairment</td><td><div><p>Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients)</p>\n</div></td><td><span title=\"Codes:{http://hl7.org/fhir/uv/cpg/CodeSystem/cpg-common-process guideline-based-care}\">Guideline-based Care</span></td><td><a href=\"PlanDefinition-TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan.html\">Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients</a></td></tr></table></div>"
  },
  "extension" : [{
    "url" : "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeCapability",
    "valueCode" : "computable"
  },
  {
    "url" : "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeRepresentationLevel",
    "valueCode" : "structured"
  },
  {
    "extension" : [{
      "url" : "method",
      "valueCodeableConcept" : {
        "coding" : [{
          "system" : "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/cs-action-combination-method",
          "code" : "exactly"
        }]
      }
    },
    {
      "url" : "threshold",
      "valuePositiveInt" : 1
    }],
    "url" : "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/ext-action-combination-method"
  }],
  "url" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommendation/therapeutic-anticoagulation",
  "version" : "1.0",
  "name" : "17 - Therapeutic Anticoagulation",
  "title" : "Therapeutic anticoagulation in non-intensive care, high-risk COVID-19 patients",
  "type" : {
    "coding" : [{
      "system" : "http://terminology.hl7.org/CodeSystem/plan-definition-type",
      "code" : "workflow-definition"
    }]
  },
  "status" : "active",
  "experimental" : true,
  "date" : "2022-02-14",
  "publisher" : "Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin e.V. (DGIIN)",
  "description" : "Bei hospitalisierten, nichtintensivpflichtigen Patienten mit COVID-19 und erhöhtem Risiko (z.B. D-Dimere ≥ 2 mg/l) kann bei niedrigem Blutungsrisiko eine therapeutische Antikoagulation, präferenziell mit NMH oder UFH, erwogen werden.",
  "action" : [{
    "title" : "Therapeutic_Anticoagulation_No_Renal_Function_Impairment",
    "description" : "Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients)",
    "code" : {
      "coding" : [{
        "system" : "http://hl7.org/fhir/uv/cpg/CodeSystem/cpg-common-process",
        "code" : "guideline-based-care"
      }]
    },
    "definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/intervention-plan/therapeutic-anticoagulation"
  }]
}